Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 394

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1A
Chunk 394
---
5: 

			Number of RSU

			Weighted Average Grant Date Fair Value

			Balance - September 30, 2023

			33,045

			$
			5.60

			Granted

			30,159

			4.56

			Balance - September 30, 2024

			63,204

			$
			5.10

			Granted

			1,227,807

			$
			2.01

			Exercised

			(31,591
			)
			 
			$
			2.27

			Forfeited

			(7,230
			)
			 
			$
			1.99

			Cancelled

			(8,537
			)
			 
			$
			1.99

			Balance - September 30, 2025

			1,243,653

			$
			2.16

The following table summarizes information about the RSUs under the 2019 Plan outstanding and exercisable at September 30, 2025:

			Number of RSU

			Exercisable at
			September 30, 2025 (#) 

			Expiry Date

			Fully-vested RSUs

			137,918

			137,918

			August 2033 - September 2035

			Vesting in the next 12 months

			250,822

			76,086

			May 2035

			Vesting from 13–24 months

			434,321

			78,435

			May 2035

			Vesting in 24 months or greater

			420,592

			40,880

			May 2035

			1,243,653

			333,319

The Company has granted RSUs with varying vesting schedules. Certain RSU’s vest immediately upon the grant date, while others vest over a period ranging from 12 to 36 months. Outstanding RSUs can be converted to Common Shares by the holder at any time after vesting and before the expiry date. As of September 30, 2025, the Company had approximately $1.8 million of unrecognized restricted share unit compensation expense, which is expected to be recognized over a